Moderna coronavirus vaccine trial shows promising early results

 

Ted S. Warren – Associated Press

In this March 16, 2020, photo, a pharmacist gives Jennifer Haller, left, the first shot in the first-stage safety study clinical trial of a potential vaccine for COVID-19, the disease caused by the new coronavirus, at the Kaiser Permanente Washington Health Research Institute in Seattle. The vaccine by Cambridge, Massachusetts-based Moderna Inc., generated antibodies similar to those seen in people who have recovered from COVID-19 in a study volunteers who were given either a low or medium dose.

The first coronavirus vaccine to be tested in people appears to be safe and able to stimulate an immune response against the infection, the manufacturer, Moderna, announced Monday, offering a glint of hope to a world desperate for ways to stop the pandemic.

The preliminary findings, in the first eight people who each received two doses of the experimental vaccine, must now be repeated in far larger tests in hundreds and then thousands of people, to find out if the vaccine can work in the real world. Moderna's technology, involving genetic material from the virus called mRNA, is relatively new and has yet to produce any approved vaccine.

https://www.startribune.com/moderna-coronavirus-vaccine-trial-shows-promising-early-results/570581362/


 

Reader Comments
(0)

 
 

Powered by ROAR Online Publication Software from Lions Light Corporation
© Copyright 2019